NasdaqCM - Nasdaq Real Time Price • USD
Tonix Pharmaceuticals Holding Corp. (TNXP)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 3 | 3 |
| Avg. Estimate | -0.47 | -0.23 | -1.57 | -1.1 |
| Low Estimate | -0.47 | -0.23 | -2.69 | -1.91 |
| High Estimate | -0.47 | -0.23 | -0.91 | -0.52 |
| Year Ago EPS | -3.25 | -2.68 | -6.85 | -1.57 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 3 | 3 |
| Avg. Estimate | 3.9M | 3.9M | 11.27M | 22.07M |
| Low Estimate | 3.9M | 3.9M | -- | 17.2M |
| High Estimate | 3.9M | 3.9M | 18M | 30M |
| Year Ago Sales | -- | -- | 7.77M | 11.27M |
| Sales Growth (year/est) | -- | -- | 45.10% | 95.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.03 | -2.75 | -1.49 | -1.64 |
| EPS Actual | -3.25 | -2.68 | -1.83 | -0.86 |
| Difference | -0.22 | 0.07 | -0.34 | 0.78 |
| Surprise % | -7.30% | 2.50% | -22.80% | 47.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.47 | -0.23 | -1.57 | -1.1 |
| 7 Days Ago | -1.35 | -1.42 | -3.14 | -1.21 |
| 30 Days Ago | -1.35 | -1.42 | -3.14 | -1.21 |
| 60 Days Ago | -1.35 | -1.42 | -4.26 | -1.91 |
| 90 Days Ago | -1.1 | -1.12 | -3.59 | -1.73 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | TNXP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 85.50% | -- | -- | 0.80% |
| Next Qtr. | 91.40% | -- | -- | 9.60% |
| Current Year | 77.10% | -- | -- | 4.50% |
| Next Year | 29.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Initiated | Dawson James: Buy | 2/28/2024 |
| Maintains | Alliance Global Partners: Buy to Buy | 8/1/2023 |
| Maintains | Alliance Global Partners: Buy to Buy | 6/2/2023 |
| Maintains | Alliance Global Partners: Buy to Buy | 8/31/2021 |
| Maintains | Alliance Global Partners: Buy to Buy | 8/11/2021 |
| Maintains | Alliance Global Partners: Buy to Buy | 2/25/2021 |
Related Tickers
IBIO iBio, Inc.
1.7700
-6.35%
JAGX Jaguar Health, Inc.
0.1771
+7.40%
ALLK Allakos Inc.
1.0600
0.00%
TCON TRACON Pharmaceuticals, Inc.
2.1100
-7.86%
VXRT Vaxart, Inc.
0.8423
-2.75%
RNAZ TransCode Therapeutics, Inc.
0.5020
-4.64%
RAPT RAPT Therapeutics, Inc.
7.93
-1.37%
FGEN FibroGen, Inc.
1.1700
-7.87%
ENSC Ensysce Biosciences, Inc.
0.5802
-7.66%
APVO Aptevo Therapeutics Inc.
0.7700
+5.91%